Streetbeat News

DXR

Daxor Corporation

https://www.daxor.com

Industry

Medical - Instruments & Supplies

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

Open

9.02

Mkt cap

45M

Volume

190K

High

9.72

P/E Ratio

7.99

52-wk high

10.04

Low

8.80

Div yield

N/A

52-wk low

7.11

Daxor has decided to withdraw its current dual 510(k)/CLIA-Waiver application after discussions with the FDA and will resubmit a focused 510(k) application.

Portfolio Pulse from Benzinga Newsdesk

September 30, 2024 | 11:29 am

Daxor Corporation's blood volume analysis (BVA) technology has been highlighted in a review published in Cardiorenal Medicine. The review emphasizes BVA's role in improving care and outcomes for cardiorenal syndrome by enhancing precision in diuretic and red cell therapies, leading to more personalized treatment.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2024 | 12:02 pm

Ascendiant Capital has maintained a Buy rating on Daxor (NASDAQ:DXR) and raised its price target from $24.5 to $24.75, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 09, 2024 | 9:57 am

Daxor Corporation has received a $300K SBIR matching fund award from Launch Tennessee to support innovation, commercialization, and job creation efforts. This funding will aid in advancing Daxor's next-generation blood volume analyzer.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 12:10 pm

Daxor Corporation reports significant financial growth in the first half of 2024, with a more than 100% increase in revenue compared to 2023. The company secured new government contracts and made strategic acquisitions to enhance its product offerings. Daxor aims for operational positive cash flow by Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

September 03, 2024 | 8:13 pm

Daxor Corporation shares are trading higher after being awarded a $1.9 million two-year contract from the U.S. Air Force to develop a point-of-care blood volume analyzer using novel fluorescent tracer and optical sensing technology.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:10 pm

Daxor Corporation has been awarded a $1.9 million two-year contract from the U.S. Air Force to develop a next-generation point-of-care blood volume analyzer using novel fluorescent tracer and optical sensing technology.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 12:05 pm

Daxor Corporation (NASDAQ:DXR) has been awarded a $550K contract extension from the U.S. Defense Health Agency to enhance its blood volume analyzer with hematocrit measurement capabilities, eliminating the need for third-party devices.

Portfolio Pulse from Benzinga Newsdesk

July 24, 2024 | 12:21 pm

Daxor Corporation (NASDAQ:DXR) has announced the acquisition of exclusive rights to Volumex, Megatope, and Glofil from Iso-Tex Diagnostics, Inc. This move is expected to enhance Daxor's diagnostics suite, improve margins, and create new revenue streams. The acquisitions are projected to be cash flow positive and accretive to earnings immediately. The manufacturing will be moved in-house to Daxor's Oak Ridge facility, with payments for the transaction spread over two years after a 6-9 month transition period. The deal is pending regulatory approvals.

Portfolio Pulse from Benzinga Newsdesk

March 25, 2024 | 12:11 pm

Daxor Corporation (NASDAQ:DXR), a leader in blood volume measurement technology, announced two significant customer transactions for its BVA-100 Blood Volume Analyzer in January 2024. The deals include a four-year lease agreement with a network of 24 hospitals across several states and a purchase by a 200-bed hospital in Mississippi. Dr. Aaron Earles highlighted the BVA's impact on patient care, noting improvements in treatment outcomes. CEO Michael Feldschuh emphasized the company's focus on commercialization and expanding its customer base.

Portfolio Pulse from Benzinga Newsdesk

February 12, 2024 | 1:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.